Sorrento Therapeutics SRNE shares are trading higher after the company received FDA clearance to proceed with its Phase 2 study for Sti-3031 in advanced urothelial carcinoma.
"These are very exciting times for Sorrento," said Dr. Henry Ji, Chairman and CEO of Sorrento. "These therapeutic antibody examples demonstrate that we are leveraging the G-MAB library to bring product candidates rapidly from preclinical development through the IND process and into clinic trials."
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19.
The stock was trading 5.46% higher at $8.86 per share at the time of writing. The stock has a 52-week high of $19.39 and a 52-week low of $2.18.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
